The odds of RFK Jr. implementing a ban on TV drug ads are slim, says our guest this week, BranchLab’s Josh Walsh. Still, pharma advertisers could face other regulatory changes over the next four years. Plus: We break down Forrester’s picks for the top 10 SSPs.
A new startup called BranchLab, which was launched earlier this year by three ad tech vets, wants to help pharma brands and health care providers apply more targeting to their TV ad campaigns – but without using actual identifiers. On Thursday, BranchLab announced the completion of a seed funding round.
Here’s today’s AdExchanger.com news round-up… Want it by email? Sign up here. Clean Bill Of Health? Everyone knows the infamous anecdote of a young woman’s early pregnancy being spotted and outed by a Target circular back in the early days of advertising-oriented predictive analytics. But big retailers still casually profile customers using a mix of […]
